Eisler Capital Management Ltd. Invests $1.35 Million in Sage Therapeutics, Inc. $SAGE

Eisler Capital Management Ltd. bought a new position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 170,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,352,000.

Other institutional investors have also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Sage Therapeutics during the first quarter worth $347,000. GAMMA Investing LLC raised its holdings in shares of Sage Therapeutics by 16,118.0% during the first quarter. GAMMA Investing LLC now owns 8,109 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 8,059 shares during the last quarter. CWM LLC raised its holdings in shares of Sage Therapeutics by 1,943.1% during the first quarter. CWM LLC now owns 61,416 shares of the biopharmaceutical company’s stock worth $488,000 after purchasing an additional 58,410 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Sage Therapeutics by 8.3% during the fourth quarter. Millennium Management LLC now owns 1,623,785 shares of the biopharmaceutical company’s stock worth $8,817,000 after purchasing an additional 124,720 shares during the last quarter. Finally, ProShare Advisors LLC raised its holdings in shares of Sage Therapeutics by 31.2% during the fourth quarter. ProShare Advisors LLC now owns 18,281 shares of the biopharmaceutical company’s stock worth $99,000 after purchasing an additional 4,350 shares during the last quarter. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Stock Performance

NASDAQ:SAGE opened at $8.68 on Thursday. The company has a fifty day moving average of $8.92 and a two-hundred day moving average of $7.85. The stock has a market capitalization of $543.54 million, a PE ratio of -1.78 and a beta of 0.26. Sage Therapeutics, Inc. has a fifty-two week low of $4.62 and a fifty-two week high of $11.44.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Wednesday, July 30th. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.17. The company had revenue of $31.66 million during the quarter, compared to analysts’ expectations of $16.69 million. Sage Therapeutics had a negative net margin of 427.78% and a negative return on equity of 67.10%. The firm’s revenue for the quarter was up 266.0% on a year-over-year basis. During the same period in the prior year, the business posted ($1.70) earnings per share. Research analysts forecast that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on SAGE shares. Piper Sandler cut shares of Sage Therapeutics from a “strong-buy” rating to a “hold” rating and reduced their target price for the stock from $9.00 to $8.50 in a report on Tuesday, June 17th. Robert W. Baird raised their target price on shares of Sage Therapeutics from $7.00 to $9.00 and gave the stock a “neutral” rating in a report on Friday, June 20th. Needham & Company LLC reissued a “hold” rating on shares of Sage Therapeutics in a report on Monday, June 16th. Wall Street Zen raised shares of Sage Therapeutics to a “hold” rating in a report on Saturday, August 2nd. Finally, Canaccord Genuity Group lifted their price objective on shares of Sage Therapeutics from $8.00 to $8.50 and gave the company a “hold” rating in a report on Tuesday, June 17th. Thirteen analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $7.85.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.